Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Icotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Beta Pharma
- 10 Jul 2017 Last checked against ClinicalTrials.gov record.
- 14 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 14 Jul 2015 Planned primary completion date changed to 1 Dec 2015 as reported by ClinicalTrials.gov.